Imperial Innovations Group Regulatory News (IVO)

2 June 2014

Imperial Innovations Group plc

Peter Chambré and Linda Wilding appointed as non-executive directors

Imperial Innovations Group plc (AIM: IVO, "Innovations"), has appointed Peter Chambré and Linda Wilding to the Board as non-executive directors. Their appointments are conditional upon the passing of the resolution to adopt new articles of association at the forthcoming General Meeting on 19 June 2014, thereby removing provisions in the existing articles relating to the maximum number of directors that may be appointed by Innovations. Their appointments will become effective immediately following the passing of the resolution.

Peter Chambré has held a number of senior executive and non-executive positions in healthcare companies, including as Chief Executive Officer of Cambridge Antibody Technology Group plc, until its acquisition by AstraZeneca PLC in 2006, Chairman of Apatech Limited (from 2008 to 2010, when it was acquired by Baxter International Inc) and non-executive director of BTG plc. He is currently Chairman of four companies operating in the healthcare sector, including Cancer Research Technology, the cancer-focused technology development and commercialisation arm of Cancer Research UK, and is also a non-executive director of Spectris plc.

Linda Wilding has extensive experience in the private equity investment and healthcare sectors. Having qualified as a chartered accountant with Ernst & Young, from 1989 to 2001 she worked in the private equity division of Mercury Asset Management, rising to the position of Managing Director. She has served as a non-executive director (including as Chairman) on the boards of a number of technology companies. She is currently Chairman of the

HG Capital Private Equity Valuation Committee and a non-executive director of UDG Healthcare plc.

Peter and Linda will, on appointment, serve on the Remuneration and the Audit and Risk Committees.

Martin Knight, Chairman of Imperial Innovations, said:

"We are delighted that we have been able to attract such high calibre candidates to our Board.

"Peter brings an impressive track record in helping businesses exploit high value opportunities based on UK innovation. He shares our passion for building substantial companies based on UK technology.

"Linda brings substantial breadth and depth of experience across both the healthcare and investment businesses. She combines an impressive career in fund management with an 18 year track record on a variety of Boards, having chaired and served on Remuneration and Audit Committees in four separate companies."

Other than the following details, there are no further details in relation to Peter Chambré and Linda Wilding to be disclosed under Rule 17 and Schedule 2 paragraph (g) of the AIM Rules.

Mr Peter Alan Chambré aged 58, is currently a director of the following companies:

· OneMed AB

· Immatics Biotechnologies GmbH

· Cancer Research Technology Limited (CRT)

· 7TM Pharma A/S

· Spectris plc

During the five year period up to the date of this announcement Peter has also served as a director of the following companies of which he is no longer a director:

· Xellia Pharmaceuticals AS

· Apatech Ltd

· BTG plc

Ms Linda Wilding (née) also known as Linda Poil aged 55, is currently a director of the following companies:

· UDG Healthcare plc

· Pacific Direct Holdings Ltd

During the five year period up to the date of this announcement Linda has also served as a director of the following companies of which she is no longer a director:

· Corin Group PLC

· Cornish Bakehouse Limited

For further information contact: